Stocks · Health care · Biological Products, (No Diagnostic Substances)

Artiva Biotherapeutics, Inc.

ARTV Clue Score30
United States Fiscal year ends December CIK 0001817241 Results filed 27 Oct 2026

What the insiders did Net buying

By person

11 insiders · 44 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Ra Capital Management, L.p. entity
Director
$92.62M (19)
—
+$92.62M
17,329,570
$72.46M
+99.3%
GC Corp. entity
10% owner
$16.50M (2)
—
+$16.50M
5,999,703
$25.09M
+31.4%
Fred Aslan
Chief Executive Officer
—
$2.08M (8)
−$2.08M
1,457,428
$6.09M
+572.7%
Christopher Horan
Chief Tech Operations Officer
—
$292.99K (4)
−$292.99K
302,321
$1.26M
+1,109%
Jennifer Bush
COO, CLO, Compliance Officer
—
$265.30K (4)
−$265.30K
357,720
$1.50M
+391.4%
Subhashis Banerjee
Chief Medical Officer
—
$191.70K (6) scheduled
−$191.70K
168,738
$705.51K
—
Heather Raymon
SVP, Research and Development
—
$27.88K (1)
−$27.88K
148,228
$619.76K
+1,382%
Thad Allen Huston
Chief Financial Officer
—
—
—
220,000
$919.84K
—
Gines Diego Miralles
President & Head of R&D
—
—
—
122,500
$512.18K
—
Neha Krishnamohan
Chief Financial Officer
—
—
—
99,356
$415.42K
+98.7%
Thorsten Graef
Chief Medical Officer
—
—
—
80,000
$334.49K
+300.0%

No percentages here. This company's share count has moved by a factor of 2.0 over the window, from 24,363,119 to 48,890,121 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.